ÂÜÀòÂÒÂ×

Scott Ellis serves as a Scientific Operating Partner at Oxford Science Enterprises, where responsibilities include collaborating with the investment team and promoting the growth of Life Science businesses while partnering with Oxford University academics. Previously, Scott held positions such as Executive Director at Novartis, overseeing the Gyroscope Research team after the acquisition of Gyroscope Therapeutics, and Head of Research and Development at Gyroscope, focusing on preclinical development and gene therapy for ocular diseases. Earlier experience includes Head of Early Development at Oxford BioMedica, where Scott managed gene and cell therapy projects, and various research roles at the Wellcome Trust Centre for Human Genetics and Brunel University London. Scott earned a Ph.D. in Retrovirology and Mouse Genetics from the National Institute for Medical Research and a BSc (Hons) in Applied Biology from the University of Bath.